CareDx (NASDAQ:CDNA) Reaches New 52-Week High After Better-Than-Expected Earnings

CareDx, Inc. (NASDAQ:CDNA)’s stock price reached a new 52-week high during trading on Friday following a better than expected earnings announcement. The stock traded as high as $42.00 and last traded at $43.4620, with a volume of 13059 shares. The stock had previously closed at $38.10.

The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.15. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The company had revenue of $131.95 million for the quarter, compared to the consensus estimate of $113.83 million. During the same period last year, the firm earned ($0.16) EPS. The firm’s revenue for the quarter was up 52.2% compared to the same quarter last year.

More CareDx News

Here are the key news stories impacting CareDx this week:

• Positive Sentiment: CareDx reported second-quarter adjusted earnings of $0.37 per share, ahead of the $0.22 consensus estimate and well above the $0.10 reported a year earlier. CareDx Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Second-quarter revenue reached $131.95 million, topping the $113.83 million analyst estimate and increasing 52.2% from the prior-year period. CareDx Announces Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 revenue outlook to $490 million–$500 million, significantly above the approximately $455.7 million consensus forecast. The upgraded guidance signals continued confidence in demand and business momentum. CareDx Q2 Non-GAAP Earnings, Revenue Rise; Lifts 2026 Revenue Outlook
• Positive Sentiment: Management’s earnings presentation and conference call reinforced the favorable results, highlighting the quarterly revenue and profitability improvement that is supporting the stronger outlook. CareDx Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Despite the earnings beat, CareDx continues to report a negative net margin and negative return on equity, so investors will watch whether the improved profitability becomes sustainable.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CDNA shares. BTIG Research lifted their price objective on CareDx from $28.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Weiss Ratings cut CareDx from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, July 15th. Wall Street Zen upgraded CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. HC Wainwright reaffirmed a “neutral” rating and issued a $46.00 price target on shares of CareDx in a research note on Friday. Finally, Craig Hallum reiterated a “hold” rating and set a $35.00 price target on shares of CareDx in a research report on Thursday, July 16th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $36.75.

Insider Activity at CareDx

In related news, Director Hannah Valantine sold 12,103 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.11, for a total value of $279,700.33. Following the transaction, the director directly owned 36,686 shares in the company, valued at approximately $847,813.46. This represents a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $29.24, for a total value of $1,166,676.00. Following the completion of the transaction, the chief executive officer owned 661,959 shares of the company’s stock, valued at $19,355,681.16. The trade was a 5.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 78,936 shares of company stock valued at $2,093,708. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On CareDx

Large investors have recently modified their holdings of the business. Deerfield Management Company L.P. purchased a new stake in shares of CareDx in the 3rd quarter valued at approximately $31,857,000. Boston Partners increased its holdings in CareDx by 2,776.5% in the 4th quarter. Boston Partners now owns 901,929 shares of the company’s stock valued at $16,994,000 after purchasing an additional 870,574 shares during the last quarter. Aberdeen Group plc acquired a new stake in CareDx in the 4th quarter valued at approximately $6,506,000. Millennium Management LLC raised its position in CareDx by 504.0% in the third quarter. Millennium Management LLC now owns 413,689 shares of the company’s stock valued at $6,015,000 after purchasing an additional 345,197 shares during the period. Finally, Palo Alto Investors LP purchased a new stake in CareDx in the third quarter valued at approximately $4,598,000.

CareDx Price Performance

The business has a 50 day simple moving average of $28.15 and a 200 day simple moving average of $22.46. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -262.01 and a beta of 2.43.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.